Pfizer and biontech provide update on rolling submission for emergency use authorization of their covid-19 vaccine in children 6 months through 4 years of age

New york & mainz, germany--(business wire)--pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced plans to extend their rolling submission to the u.s. food and drug administration (fda) seeking to amend the emergency use authorization of the pfizer-biontech covid-19 vaccine to include children 6 months through 4 years of age, which had been requested by fda. the trial in children 6 months through 4 years of age is ongoing and data on the first two 3 Μg doses in this age group a
BNTX Ratings Summary
BNTX Quant Ranking